Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
On Thursday, H.C. Wainwright reaffirmed its Buy rating and $60.00 price target for Precision BioSciences Inc . (NASDAQ:DTIL), following the company’s recent presentation of promising preclinical data. Currently trading at $5.01, the stock has significant upside potential according to analysts, whose targets range from $19 to $60. The data was unveiled at the 2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas, which took place on March 19. According to InvestingPro analysis, the company maintains a "GOOD" overall financial health score of 2.71.
Precision BioSciences announced its findings related to PBGENE-DMD, a gene editing therapeutic candidate aimed at treating Duchenne muscular dystrophy (DMD). The treatment demonstrated significant and long-lasting expression of near full-length dystrophin protein. This protein is crucial for muscle function and is lacking in individuals with DMD. The preclinical study, conducted using a humanized DMD mouse model, showed that PBGENE-DMD restored muscle function to near-maximum levels over a six-month period. The company’s strong financial position is evident in its impressive revenue growth of 43.6% and a healthy current ratio of 9.22, indicating robust liquidity.
Analysts at H.C. Wainwright believe that these preclinical outcomes provide a strong foundation for moving the PBGENE-DMD program into clinical trials. The firm’s position is that the data supports the continued development of the treatment, and they have reiterated their confidence in the stock with a Buy rating and a $60.00 price target. InvestingPro data reveals the company holds more cash than debt on its balance sheet, with additional financial insights available to subscribers.
Precision BioSciences’ approach with PBGENE-DMD involves a muscle-targeted in vivo gene editing technique. This method has the potential to address the underlying genetic cause of Duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle degeneration and weakness.
The reiteration of the Buy rating and price target by H.C. Wainwright underscores their anticipation for Precision BioSciences’ progress in the gene editing space, particularly for treatments aimed at serious genetic diseases like DMD. Precision BioSciences’ stock performance and investor sentiment may be influenced by these developments and the potential for the PBGENE-DMD program to advance into clinical stages.
In other recent news, Precision BioSciences has received FDA clearance to expand its Phase 1 ELIMINATE-B study for PBGENE-HBV, a gene editing therapy aimed at potentially curing chronic hepatitis B, to the United States. This trial, which is already underway in Moldova, Hong Kong, and New Zealand, is significant as it targets a disease affecting over one million Americans. The company has reported promising safety and efficacy data from the lowest dose level in the ongoing trial. Meanwhile, H.C. Wainwright has maintained a Buy rating on Precision BioSciences, with a price target of $60, following the announcement of preliminary safety and antiviral activity data from the ELIMINATE-B study. In another development, Precision BioSciences announced the retirement of Dr. Sam Wadsworth from its Board of Directors, effective early 2025, with no immediate impact on the company’s strategic direction. Additionally, BMO Capital Markets upgraded the company’s stock from Market Perform to Outperform, setting a price target of $34, citing favorable clinical data from a related trial for Ornithine Transcarbamylase deficiency. These developments reflect continued confidence in Precision BioSciences’ ARCUS gene editing platform and its potential to transform the management of genetic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.